Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1632-1642

  Sugino, Haruhiko ^a   Watanabe, Akihito ^b   Amada, Naoki ^b   Yamamoto, Miho ^b   Ohgi, Yuta ^b   Kostic, Dusan ^c   Sanchez, Raymond ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c OPDC   (United States)

Author keywords

biomarker; drug development; early stage; Key words Alzheimer disease (AD); mild cognitive impairment (MCI)

Indexed keywords

BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL (TOPIC); COGNITION; DAILY LIFE ACTIVITY; DISEASE ASSESSMENT; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; BLOOD; DRUG APPROVAL; HEALTH; METHODOLOGY;

ALZHEIMER DISEASE; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; GLOBAL HEALTH; HUMANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; RESEARCH DESIGN;

EID: 84940608093     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.07.006     Document Type: Article

References (64)

1. Alzheimer's Disease International Dementia statistics 2013 Alzheimer's Disease International London, UK
2. Alzheimer's Disease International Alzheimer's Disease 2013 Alzheimer's Disease International London, UK
3. Alzheimer's Association National Plan Milestone Workgroup K.N. Fargo, P. Aisen, M. Albert, and et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers 10 2014 S430 S452
4. M.D. Hurd, P. Martorell, and K.M. Langa Monetary costs of dementia in the United States N Engl J Med 369 2013 489 490
5. Alzheimer's Association 2014 Alzheimer's disease facts and figures Alzheimers Dement 10 2014 e47 e92
6. J. Mintzer, D. Mirski, and K. Hoernig Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint Dialogues Clin Neurosci 2 2000 139 155
7. M.S. Beeri, P. Werner, M. Davidson, and S. Noy The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients Int J Geriatr Psychiatry 17 2002 403 408
8. H. Brodaty, and M. Donkin Family caregivers of people with dementia Dialogues Clin Neurosci 11 2009 217 228
9. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: few candidates, frequent failures Alzheimers Res Ther 6 2014 37
10. H.W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain 129 2006 2840 2855
11. S. Salomone, F. Caraci, G.M. Leggio, and et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Br J Clin Pharmacol 73 2012 504 517
12. L.S. Schneider, F. Mangialasche, N. Andreasen, and et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 J Intern Med 275 2014 251 283
13. S. Madhusoodanan, and M.B. Ting Pharmacological management of behavioral symptoms associated with dementia World J Psychiatry 4 2014 72 79
14. K.I. Kaitin, and C.P. Milne A dearth of new meds Sci Am 305 2011 16
15. J. Arrowsmith, and P. Miller Trial watch: phase II and phase III attrition rates 2011-2012 Nat Rev Drug Discov 12 2013 569
16. M. Hay, D.W. Thomas, J.L. Craighead, and et al. Clinical development success rates for investigational drugs Nat Biotechnol 32 2014 40 51
17. K. Iqbal, C. Alonso Adel, S. Chen, and et al. Tau pathology in Alzheimer disease and other tauopathies Biochim Biophys Acta 1739 2005 198 210
18. A. Kumar, and A. Singh Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update Pharmacol Rep 67 2015 195 203
19. Q. Jia, Y. Deng, and H. Qing Potential therapeutic strategies for Alzheimer's disease targeting or beyond beta-amyloid: insights from clinical trials Biomed Res Int 2014 2014 837157
20. S. Salloway, R. Sperling, N.C. Fox, and et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
21. N. Relkin Clinical trials of intravenous immunoglobulin for Alzheimer's disease J Clin Immunol 34 Suppl 1 2014 S74 S79
22. R.S. Doody, R.G. Thomas, M. Farlow, and et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
23. H. Engler, A. Forsberg, O. Almkvist, and et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2006 2856 2866
24. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
25. C. Pater Mild cognitive impairment (MCI) - the novel trend of targeting Alzheimer's disease in its early stages - methodological considerations Curr Alzheimer Res 8 2011 798 807
26. M. Wortmann Dementia: a global health priority - highlights from an ADI and World Health Organization report Alzheimers Res Ther 4 2012 40
27. G8 Health and Science Ministers G8 Dementia Summit 2013 UK Department of Health Communique. London, UK
28. ® convenes health leaders from around the world to discuss global action against dementia 2014 Alzheimer's Association Chicago
29. World Health Organization. First WHO Ministerial Conference on Global Action Against Dementia. Vol 2015. Geneva, Switzerland: World Health Organization; 2015.
30. G. Vradenburg A pivotal moment in Alzheimer's disease and dementia: how global unity of purpose and action can beat the disease by 2025 Expert Rev Neurother 15 2015 73 82
31. US Food and Drug Administration Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease 2013 Center for Drug Evaluation and Research Washington, DC
32. European Medicines Agency Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. Vol EMA/CHMP/539931 2014 European Medicines Agency London 1 33
33. European Medicines Agency. Concept paper on need for revision of the guideline on medicinal products for the treatment of Alzheimer's Disease and other dementias. EMA/CHMP/617734/2013, 2013.
34. M.S. Albert, S.T. DeKosky, D. Dickson, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
35. P.J. Visser, S. Vos, I. van Rossum, and P. Scheltens Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease Alzheimers Dement 8 2012 560 563
36. S.E. O'Bryant, L.H. Lacritz, J. Hall, and et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database Arch Neurol 67 2010 746 749
37. K. Ong, V.L. Villemagne, A. Bahar-Fuchs, and et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment Alzheimers Res Ther 5 2013 4
38. J. de Lartigue Flutemetamol (18F): a beta-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis Drugs Today (Barc) 50 2014 219 229
39. O. Sabri, J. Seibyl, C. Rowe, and H. Barthel Beta-amyloid imaging with florbetaben Clin Transl Imaging 3 2015 13 26
40. Committee for Medicinal Products for Human Use/European Medicines Agency Guideline on clinical evaluation of diagnostic agents Rev 1 ed 2009 European Medicines Agency London
41. P.A. Adlard, B.A. Tran, D.I. Finkelstein, and et al. A review of beta-amyloid neuroimaging in Alzheimer's disease Front Neurosci 8 2014 327
42. M.C. Carrillo, L.J. Bain, G.B. Frisoni, and M.W. Weiner Worldwide Alzheimer's disease neuroimaging initiative Alzheimers Dement 8 2012 337 342
43. J.Q. Trojanowski, H. Vandeerstichele, M. Korecka, and et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement 6 2010 230 238
44. G.M. McKhann, D.S. Knopman, H. Chertkow, and et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
45. R.A. Sperling, P.S. Aisen, L.A. Beckett, and et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
46. Z.S. Khachaturian Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 253 256
47. B. Dubois, H.H. Feldman, C. Jacova, and et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629
48. National Institutes of Health Accelerating Medicines Partnership[#,63]?> Vol 2015 2014 National Institutes of Health Bethesda, Md
49. Innovative Medicines Initiative 11th Call for Proposals 2013 3 ed 2013 Innovative Medicines Initiative Brussels, Belgium 1 173
50. C. Liggins, H.M. Snyder, N. Silverberg, and et al. International Alzheimer's Disease Research Portfolio (IADRP) aims to capture global Alzheimer's disease research funding Alzheimers Dement 10 2014 405 408
51. S.M. Mills, J. Mallmann, A.M. Santacruz, and et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris) 169 2013 737 743
52. R.A. Sperling, D.M. Rentz, K.A. Johnson, and et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13
53. F. Panza, V. Solfrizzi, B.P. Imbimbo, and et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease Expert Rev Neurother 14 2014 973 986
54. K.W. Menting, and J.A. Claassen beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease Front Aging Neurosci 6 2014 165
55. D.S. Knopman Clinical trial design issues in mild to moderate Alzheimer disease Cogn Behav Neurol 21 2008 197 201
56. D. Wilkinson, K. Windfeld, and E. Colding-Jorgensen Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 13 2014 1092 1099
57. W.J. Deardorff, A. Shobassy, and G.T. Grossberg Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication Expert Rev Neurother 15 2015 7 17
58. F. Piette, J. Belmin, H. Vincent, and et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial Alzheimers Res Ther 3 2011 16
59. K. Maeda, H. Sugino, H. Akazawa, and et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator J Pharmacol Exp Ther 350 2014 589 604
60. Biogen Idec presents positive interim results from Phase 1B study of investigational Alzheimer's disease treatment aducanumab (BIIB037) at 2015 AD/PD™ Conference [press release]. Cambridge, Mass: Biogen Idec; 2015. http://www.biogenidec.com/press-release-details.aspx?ID=14712&Action=1&Newsld=2486&M=NewsV2&PID=619972015. Accessed March 21, 2015.
61. Biogen Idec. Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease. 2000-2015 ed. Bethesda, Md: National Library of Medicine; 2014.
62. Center for Drug Evaluation and Research Continuing America's Leadership: The Future of Medical Innovation for Patients 2015 US Department of Health and Human Services Washington, DC
63. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed February 28, 2015.
64. Alzheimer Research Forum. http://www.alzforum.org. Accessed February 28, 2015.